|NuvOx Pharma||NuvOx Pharma is a clinical stage biotechnology company developing a first-in-class oxygen therapeutic to treat life-threatening diseases where hypoxia plays a role.|
|Denovo Biopharma||The core technology is the industry’s first platform and algorithm to perform de novo genomic biomarker discovery retrospectively using archived clinical samples. This technology is especially useful for late stage clinical drugs that have completed trials with unsatisfactory efficacy. By identifying biomarkers correlated to patients’ responsiveness to drug candidates retrospectively, our technology enables biotech and pharmaceutical companies to design new clinical trials in a targeted patient population to achieve significant efficacy and/or less adverse effects.|
|Neologics Bioscience|| NeoLogics Bioscience Co., Ltd was founded in Suzhou, 2018. Currently it is a pre-clinical stage biotech company focusing on biologics for immune modulation. The disease areas cover cancer, autoimmune and inflammation.|
Our company is committed to lead the innovation of truly BIC (best in class) and FIC (first in class) biological immunotherapies for the benefit of patients worldwide. We have integrated robust in silico data mining, analyzing and phenotypical target validation system to ensure a sustainable pipeline. We also leverage
resources from mature CRO, CDMO in China to advance our pipeline to certain milestones.
For the present, we have two drug candidates in IND enabling stage and 5 candidates in early discovery stage. We have just secured 15Mn $ pre-A round financing and are looking for talents to join us.
|DotBio||DotBio is a highly innovative biopharmaceutical company with a mission to harness next-generation antibody technologies to bring more effective therapies to patients. DotBio takes an innovative therapeutic approach towards the ideal treatment: the rapid prototyping of multi-functional antibodies to identify molecules with synergistic activity combinations, optimal architectures and unique mechanisms of action. DotBio’s approach involves the use of its modular DotBody technology platform, its CoFi and Hot-CoFi stabilization technologies, high-throughput miniaturized assays and data analytics to generate unique therapeutic molecules that target both extracellular and intracellular disease drivers. DotBio is a platform company with a growing portfolio of assets, including numerous target-specific DotBody modules, as well as numerous preclinical assets in the immuno-oncology field.|
For more information about DotBio, please visit: http://www.dotbio.com.
|ANTABIO||The company is a private biopharmaceutical company developing novel and highly differentiated antibacterial treatments for critical priority pathogens with a particular focus on life-threatening respiratory infections.|
|Vésale Bioscience||Vésale Bioscience is a Belgian biotech. We fight antibiotic multi-resistant infections with personalized phage therapy solutions for human and veterinary use, combining a fast automated diagnostic tool with a library of phages that we can GMP produce.|
In December 2021, Vésale Bioscience has been awarded by BioFIT The most innovative start-up in Life Sciences in Europe, out of 90+ projects.
We will launch our phage therapy solutions in Europe in 2023 and are seeking commercial partners in Asia and the rest of the World.
In the meantime, we are also looking for investors to take part in our Series A round of €6M in Q1 2022, prior to sizable Series B within 12-18 months followed by IPO.
More info on www.phage.health
|VaRi Bioscience GmbH||VaRi Bioscience is a newly established biotech company focussing on innovative female health projects by applying a vaginal ring drug delivery technology with long-acting properties (3 months)|
|Ophidion, Inc.||The company focused on treating neiurodegenerative diseases by delivering gene-silencing therapeutics selectively and directly into the brain following intravenous administration. Our lead pipeline programs deliver internally-discovered and patented gene-silencing oligonucleotides (short interfering ribonucleic acids [siRNA’s] or antisense oligonucleotides [ASO’s]) that are complexed to our patented Trojan horse technology to slow the progression of neurodegenerative disorders such as Huntington’s disease and to improve cognitive function in other neurodegenerative diseases such as Alzheimer’s or Parkinson’s.|
|Turn Therapeutics||The company is a concept-to-approval research and development organization focused on novel, best in class products for infection control, skin disease, and wound care. The company’s proprietary technologies are used every day by world-leading healthcare institutions to care for a variety of skin and wound conditions. For more information, visit www.turntherapeutics.com.|
|Affamed Therapeutics||AffaMed Therapeutics is a late clinical-stage biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs in ophthalmology, neurology and psychiatric disorders for patients in Greater China and around the world. The management team of AffaMed Therapeutics has deep industry expertise and an extensive track record in high-quality clinical development, regulatory affairs, CMC, business development, and operations both in China and with leading global pharmaceutical companies.|
AffaMed is well-positioned to accelerate clinical development of potential new therapies that aim to make a tangible difference in patients’ lives.
| OncoOne||Cancer is a major cause of morbidity and mortality, with an estimated 18.1 million newly diagnosed patients per year and 9.6 million cancer-related deaths in 2018 (WHO, International Agency for Research on Cancer, September 12th, 2018). Although new therapies have seen substantial success in treating this widespread disease, difficult issues remain, such as the development of resistance mechanisms, off-target cytotoxicity and lack of efficacy.|
In an effort to contribute to the global fight against cancer, OncoOne leverages our proprietary drug development know-how to create first-in-class, novel, and highly potent therapeutics in order to treat underserved patients suffering from solid tumor cancers.
As a business model, OncoOne intends to ensure that we strive to apply state-of-the-art technologies and the highest possible quality standards in order to establish a successful and continuously evolving life science company.